Maddi Hebebrand, MC, Associate Editor

Patients treated with deucravacitinib achieved higher ACR20 response rates at week 16 than those receiving placebo in the POETYK PsA studies.

A newly defined Nodularity Index, measuring tumor depth relative to width, independently predicted melanoma-specific survival.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

At week 16, 73.3% of patients receiving delgocitinib achieved a clinically meaningful improvement (≥ 4 points) in Dermatology Life Quality Index score vs 47.8% with vehicle.

This FAQ answers top questions of HS therapy: when to escalate to biologics, add surgery, measure success, and support mental health.

Clearance rates increased between days 29 and 57, with the highest activity observed in the 200-μg treatment group.

Baker explains why competency-based autonomy and structured collaboration are essential in high-acuity medical dermatology.

A qualitative study found that hidradenitis suppurativa (HS) significantly influences patients’ daily decisions, emotional health, relationships, and financial stability.

A panel discussion highlights the diagnostic variability, systemic risk, and evolving treatment landscape of GPP.

Rocatinlimab had met primary end points in large phase 3 trials and was previously expected to move toward regulatory submission in 2026.

The double-blind, randomized, placebo-controlled ARQ-234-131 study will assess safety, tolerability, pharmacokinetics, and early signs of clinical activity.

Skin adverse events linked to immunotherapy may correlate with improved tumor response and survival, underlining their clinical significance.

The final case described a young woman with clinically mild hidradenitis suppurativa (HS) but significant emotional and social distress, prompting some of the most passionate discussion across the 3 roundtables.

Over 70% of evaluable patients achieved near-clear or clear skin after nearly 3 years of treatment with nemolizumab.

In a Derm Dispatch discussion, Renata Block, DMSc, MMS, PA-C, and Lauren Madigan, MD, review practical strategies for diagnosing and managing cutaneous mastocytosis across age groups.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Shanna Miranti, MPAS, PA-C, discuss how “taking off the clinician mask” can strengthen trust and improve shared decision-making in the exam room.

This case involved a young patient with mild to moderate hidradenitis suppurativa (HS) of the axillae, characterized by intermittent, limited lesions without tunneling or scarring. Although seemingly routine, it prompted deeper reflection.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Dermatology Times is recapping our exclusive expert interviews from the month of February.

The first case involved a middle-aged patient with severe, long-standing hidradenitis suppurativa (HS) marked by years of active disease with extensive sinus tracts, dense scarring, chronic drainage, frequent flares, constant pain, limited mobility, and a daily life centered around symptom management.

Barzolvolimab is a humanized monoclonal antibody that inhibits the KIT receptor, aiming to reduce mast cell survival and activity in chronic spontaneous urticaria.

More than 57% of patients with ACD reported moderate to severe quality-of-life impairment, with symptoms and embarrassment among the most affected areas.

In an interview with Dermatology Times, Michael O’Donoghue, MD, describes how a standardized protocol supports efficient and consistent delivery of photodynamic therapy.

Transcriptomic analysis revealed that chronic hand eczema shares overlapping immune signatures with both atopic dermatitis and psoriasis.

In a 52-week phase 3 study, CT-P43 demonstrated sustained efficacy comparable to reference ustekinumab in adults with moderate to severe plaque psoriasis.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

In a conversation with Dermatology Times, Del Rosso highlighted the growing range of systemic and procedural therapies available to clinicians.

Michael O’Donoghue, MD, outlines how delegating PDT workflows to trained medical assistants can preserve physician time while maintaining treatment quality.

A post hoc analysis found that abrocitinib provided faster itch relief than dupilumab in adults with itch-dominant atopic dermatitis.